Rchr
J-GLOBAL ID:202001003926606684   Update date: Aug. 29, 2024

OKAZAKI Shogo

オカザキ ショウゴ | OKAZAKI Shogo
Affiliation and department:
Job title: Assistant Professor
Research field  (1): Tumor biology
Research theme for competitive and other funds  (6):
  • 2024 - 2027 歯周病発症機序のパラダイムシフトへの挑戦 ーヒト化マウスでのウイルス関与の立証 ー
  • 2022 - 2025 セロトニンシグナルを標的とした扁平上皮癌分化誘導療法の開発
  • 2022 - 2025 Actionable遺伝子変異に基づく新たな口腔扁平上皮癌治療戦略の開発
  • 2020 - 2022 Functional analysis of serotonin signaling in the progression of squamous cell carcinoma
  • 2018 - 2020 Analysis of antitumor effect mechanism by dopamine signal inhibitor
Show all
Papers (33):
  • Keiko Fujisaki, Shogo Okazaki, Shuhei Ogawa, Miyama Takeda, Eiji Sugihara, Kenichi Imai, Seiya Mizuno, Satoru Takahashi, Ryo Goitsuka. B Cells of Early-life Origin Defined by RAG2-based Lymphoid Cell Tracking under Native Hematopoietic Conditions. Journal of immunology (Baltimore, Md. : 1950). 2024
  • Atsuya Sawabe, Shogo Okazaki, Akira Nakamura, Ryo Goitsuka, Tomonori Kaifu. The orphan G protein-coupled receptor 141 expressed in myeloid cells functions as an inflammation suppressor. Journal of leukocyte biology. 2024
  • Akitaka Yamasaki, Kumiko Maruyama-Takahashi, Kento Nishida, Shogo Okazaki, Kouki Okita, Yasutoshi Akiyama, Hideaki Suzuki, Yuichi Endo, Kazue Masuko, Takashi Masuko, et al. CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2 / CD98 antibody inhibits the growth signal of human breast cancer cells. Genes to Cells. 2023
  • Akitaka Yamasaki, Rikuto Miyake, Yuta Hara, Hideki Okuno, Takuya Imaida, Kouki Okita, Shogo Okazaki, Yasutoshi Akiyama, Kenji Hirotani, Yuichi Endo, et al. Dual-targeting therapy against HER3 / MET in human colorectal cancers. Cancer Medicine. 2023
  • Juntaro Yamasaki, Yuki Hirata, Yuji Otsuki, Kentaro Suina, Yoshiyuki Saito, Kenta Masuda, Shogo Okazaki, Takatsugu Ishimoto, Hideyuki Saya, Osamu Nagano. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer. Cancer science. 2022. 113. 3. 916-925
more...
MISC (17):
  • Shogo Okazaki, Yuki Nakano, Momoko Yoshikawa, Tomoya Soma, Seiji Asoda, Ryo Goitsuka, Hideyuki Saya, Osamu Nagano. Transcription factor FOXA1 is a negative regulator for xCT-dependent tumor formation in oral cancer. CANCER SCIENCE. 2022. 113. 1324-1324
  • 齋藤潤, 齋藤潤, 大西伸幸, 杉原英志, 清水孝恒, 清水孝恒, 木村聖美, 小池直義, 小池直義, サンペトラ オルテア, et al. Benzaldehydeは癌細胞のAxl受容体の発現を14-3-3ζを介して抑制し,Osimertinibによる治療抵抗性を制する. 日本癌学会学術総会抄録集(Web). 2021. 80th
  • Shintaro Nakamura, Hiroyuki Ozawa, Juntaro Yamasaki, Shogo Okazaki, Momoko Yoshikawa, Tomoya Soma, Seiji Asoda, Osamu Nagano, Mariko Sekimizu, Shin Saito, et al. Pimozide combined with paclitaxel demonstrates a significant antitumor effect in head and neck squamous cell carcinoma. CANCER RESEARCH. 2020. 80. 16
  • 推名 健太郎, 山崎 淳太郎, 大槻 雄士, 平田 雄紀, 岡崎 章悟, 土橋 賢司, サンペトラ・オルテア, 光石 陽一郎, 高橋 史行, 高橋 和久, et al. 小細胞肺癌において、xCTはがん幹細胞性に寄与する(xCT confers cancer stem-like properties in small cell lung cancer cells). 日本癌学会総会記事. 2019. 78回. E-1102
  • Shohei Kamenori, Kentaro Suina, Juntaro Yamasaki, Subaru Shintani, Yuji Otsuki, Yuki Hirata, Shogo Okazaki, Kenji Tsuchihashi, Oltea Sampetrean, Yoichiro Mitsuishi, et al. SLC7A11 expression confers cancer stem-like properties in small cell lung cancer cells. CANCER RESEARCH. 2019. 79. 13
more...
Education (2):
  • 2012 - 2016 Keio University 医学研究科
  • 2010 - 2012 Kinki University 薬学研究科
Professional career (1):
  • Doctor of Medical Science (Keio University)
Work history (2):
  • 2018/09 - 2022/03 Tokyo University of Science Research Institute for Biomedical Sciences Assistant Professor
  • 2016/04 - 2018/08 Keio University Division of Gene Regulation, Institute for Advanced Medical Research, Graduate School of Medicine Project Assistant Professor
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page